Altimmune announces completion of dosing in the phase 2 momentum trial of pemvidutide in subjects with obesity or overweight

Gaithersburg, md., sept. 12, 2023 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced the completion of dosing (last subject last dose) in its 48-week phase 2 momentum trial evaluating the efficacy and safety of pemvidutide in subjects with obesity or overweight.
ALT Ratings Summary
ALT Quant Ranking